Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.|Faculdade de Medicina, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
André P
AP
Fay
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.|University Hospital del Mar, IMIM, Barcelona, Spain.
Joaquim
J
Bellmunt
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents